FindTrial
Sign In

Median effective plasma concentration of remifentanil inhibiting cardiovascular response to CO2 pneumoperitoneum stimulus when combined with propofol in patients undergoing laparoscopic gynaecological surgery

Median effective plasma concentration of remifentanil inhibiting cardiovascular response to CO2 pneumoperitoneum stimulus when combined with propofol in patients undergoing laparoscopic gynaecological surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16010257
Enrollment
Unknown
Registered
2016-12-26
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic gynaecological surgery

Interventions

Study group:propofol and remifentanil

Sponsors

Southern District of Anhui Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective laparoscopic gynaecological surgery; 2. Aged 20-60 years; 3. BMI 18-30 kg/m2; 4. ASA physical status I-II.

Exclusion criteria

Exclusion criteria: 1. History of cardiac, pulmonary, liver or renal disease; 2. Drug or alcohol abuse; 3. Current use of any vasoactive medications; 4. Recent use of any medications known to affect sympathetic adrenergic response

Design outcomes

Primary

MeasureTime frame
Median effective plasma concentration of remifentanil inhibiting cardiovascular response to CO2 pneumoperitoneum stimulus when combined with propofol in patients undergoing laparoscopic gynaecological surgery;—

Secondary

MeasureTime frame
Mean arterial pressure;Heart rate;—

Countries

China

Contacts

Public ContactLi Juan

Southern District of Anhui Provincial Hospital

huamuzi1999@126.com+86 13956005465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026